Journal article · 2026 · Open access

Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)

Atul Malhotra, Daniel J. Gottlieb, Holger Woehrle, Ellen B. Dennehy, Giulia Calamai, Zhuqing Liu, Sujatro Chakladar, Ronan Grimes, Beverly L. Falcón, Vaishnavi Kundel, ATTAIN-OSA Investigators, Juan José Morales Virgen and 65 more

JAMA · Published 9 November 2026 · DOI 10.1001/jama.2026.24080

Open full textView at the publisherCite this paper

In brief

“Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)” is a 2026 journal article by Atul Malhotra and 76 co-authors, published in JAMA. OpenAlex counts 2 citations as of 18 November 2026, which puts it in the top 6% of works published in 2026 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
5.40
References
39
Authors
77

Abstract

Importance: Obstructive sleep apnea (OSA) is a common disorder characterized by repeated upper airway collapse during sleep that is associated with reduced quality of life and increased incidence of cardiometabolic disease. Objective: To assess the effects of orforglipron on moderate to severe OSA in adults with obesity or overweight, compared with placebo. Design, Setting, and Participants: Two 52-week, phase 3, multicenter, double-blind, placebo-controlled randomized clinical trials were conducted at 66 sites in the US, Argentina, Brazil, China, Czech Republic, Germany, Japan, Mexico, and Taiwan. Adults with moderate to severe OSA and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 27 or higher were enrolled between November 11, 2024, and July 23, 2025. Final follow-up occurred on July 30, 2026. Trial 1 included patients not receiving positive airway pressure treatment and trial 2 included patients receiving positive airway pressure treatment. Intervention: Patients were randomized (1:1) to receive either once-daily orforglipron (maximum tolerated dose: equivalent to 9-, 14.5-, or 17.2-mg tablet dose) or placebo. Main Outcomes and Measures: The primary end point was change in apnea-hypopnea index (AHI, events/h) from baseline to week 52. Seven key multiplicity-controlled secondary end points included change in sleep apnea-specific hypoxic burden, the Patient-Reported Outcomes Measurement Information System Short Form Sleep-Related Impairment T-score, and high-sensitivity C-reactive protein. Results: A total of 363 patients were randomized in trial 1 (mean age, 48.4 years; BMI, 37.4; AHI, 50.7 events/h; 31.4% female) and 349 patients were randomized in trial 2 (mean age, 51.1 years; BMI, 38.6; AHI, 57.6 events/h; 26.9% female). For the treatment regimen estimand, in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001) at 52 weeks. In trial 2, the mean AHI change was -17.3 for orforglipron and -5.3 for placebo (difference, -12.0 [95% CI, -17.1 to -6.9]; P < .001) at 52 weeks. Of 7 key secondary end points, 6 were statistically significant, favoring orforglipron. Gastrointestinal events were the most commonly reported adverse events, occurring in 123 (68.0%) participants randomized to receive orforglipron vs 68 (37.4%) randomized to receive placebo in trial 1 and in 125 (70.6%) participants randomized to receive orforglipron vs 63 (36.6%) randomized to receive placebo in trial 2. Conclusions and Relevance: These results provide evidence for the potential use of oral orforglipron to improve sleep-disordered breathing in adults with moderate to severe OSA and obesity or overweight. Trial Registration: ClinicalTrials.gov Identifier: NCT06649045.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Malhotra, A., Gottlieb, D. J., Woehrle, H., Dennehy, E. B., Calamai, G., Liu, Z., Chakladar, S., Grimes, R., Falcón, B. L., Kundel, V., ATTAIN-OSA Investigators, Virgen, J. J. M., Salazar, M. A., Li, H.-Y., Costanzo, P., Vutikullird, A., rholz, T. S. U., Shirahama, R., Larrateguy, L., . . . Cheng, Z. (2026). Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. https://doi.org/10.1001/jama.2026.24080

MLA 9

Malhotra, Atul, et al. “Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).” JAMA, 2026. https://doi.org/10.1001/jama.2026.24080.

Chicago

Malhotra, Atul, Daniel J. Gottlieb, Holger Woehrle, Ellen B. Dennehy, Giulia Calamai, Zhuqing Liu, Sujatro Chakladar, et al. 2026. “Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).” JAMA. https://doi.org/10.1001/jama.2026.24080.

Harvard

Malhotra, A. et al. (2026) ‘Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)’, JAMA. doi:10.1001/jama.2026.24080.

IEEE

A. Malhotra et al., “Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA),” JAMA, 2026, doi: 10.1001/jama.2026.24080.

BibTeX

@article{malhotra2026orforglipron,
  title     = {{Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)}},
  author    = {Malhotra, Atul and Gottlieb, Daniel J. and Woehrle, Holger and Dennehy, Ellen B. and Calamai, Giulia and Liu, Zhuqing and Chakladar, Sujatro and Grimes, Ronan and Falcón, Beverly L. and Kundel, Vaishnavi and ATTAIN-OSA Investigators and Virgen, Juan José Morales and Salazar, Melchor Alpízar and Li, Hsueh-Yu and Costanzo, Pablo and Vutikullird, Apinya and rholz, Thomas Sch uuml and Shirahama, Ryutaro and Larrateguy, Luis and Soucie, Gary and Lederer, Katharina and Wang, Guixia and Gohma, Iwao and Jiang, Xiaozhen and Hudson, John and Nakamura, Kei and Maldonado, Francisco Lopez and Cercato, Cíntia and Hang, Liang-Wen and Schaum, Thomas and others},
  journal   = {JAMA},
  year      = {2026},
  doi       = {10.1001/jama.2026.24080},
  url       = {https://doi.org/10.1001/jama.2026.24080}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research

  • orforglipron
  • obstructive sleep apnea
  • obesity
  • apnea-hypopnea index
  • positive airway pressure
  • hypoxic burden
  • sleep-related impairment
  • C-reactive protein

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Malhotra, A., Gottlieb, D. J., Woehrle, H., Dennehy, E. B., Calamai, G., Liu, Z., Chakladar, S., Grimes, R., Falcón, B. L., Kundel, V., ATTAIN-OSA Investigators, Virgen, J. J. M., Salazar, M. A., Li, H.-Y., Costanzo, P., Vutikullird, A., rholz, T. S. U., Shirahama, R., Larrateguy, L., . . . Cheng, Z. (2026). Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. https://doi.org/10.1001/jama.2026.24080

How many times has this paper been cited?

2 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Atul Malhotra, Daniel J. Gottlieb, Holger Woehrle, Ellen B. Dennehy, Giulia Calamai, Zhuqing Liu, Sujatro Chakladar, Ronan Grimes, Beverly L. Falcón, Vaishnavi Kundel, ATTAIN-OSA Investigators, Juan José Morales Virgen and 65 more.

What is the DOI of this paper?

10.1001/jama.2026.24080, permanently at https://doi.org/10.1001/jama.2026.24080. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.